Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

• Published in: The Lancet (British edition) 2022-12, Vol.400 (10367), p.1938-1952
• Main Authors: Mebazaa, Alexandre, Davison, Beth, Chioncel, Ovidiu, Cohen-Solal, Alain, Diaz, Rafael, Filippatos, Gerasimos, Metra, Marco, Ponikowski, Piotr, Sliwa, Karen, Voors, Adriaan A, Edwards, Christopher, Novosadova, Maria, Takagi, Koji, Damasceno, Albertino, Saidu, Hadiza, Gayat, Etienne, Pang, Peter S, Celutkiene, Jelena, Cotter, Gad
• Format: Article
• Language: English
• Subjects: Adverse events; Angiotensin; Blood pressure; Brain natriuretic peptide; Cardiology; Cardiology and cardiovascular system; Congestive heart failure; Death; Effectiveness; Enzymes; Female; Health services; Heart Failure; Hospitals; Human health and pathology; Humans; Laboratories; Life Sciences; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - therapeutic use; Minority & ethnic groups; Missing data; Mortality; Patients; Peptides; Potassium; Quality of Life; Renin; Risk; Risk reduction; Safety; Stroke Volume; Titration; Treatment Outcome; Ventricle; Ventricular Function, Left
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(22)02076-1

There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete. Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (